|
Malignant neoplasm of prostate
|
0.140 |
Biomarker
|
disease |
BEFREE |
Our findings revealed that miR-203/RGS17 axis might be a potential therapeutic target for the treatment of PCa.
|
31298318 |
2019 |
|
Malignant neoplasm of prostate
|
0.140 |
Biomarker
|
disease |
BEFREE |
Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products.
|
28621943 |
2017 |
|
Malignant neoplasm of prostate
|
0.140 |
Biomarker
|
disease |
BEFREE |
RGS17: an emerging therapeutic target for lung and prostate cancers.
|
23734683 |
2013 |
|
Prostate carcinoma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
|
29351497 |
2018 |
|
Prostate carcinoma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Our findings revealed that miR-203/RGS17 axis might be a potential therapeutic target for the treatment of PCa.
|
31298318 |
2019 |
|
Prostate carcinoma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products.
|
28621943 |
2017 |
|
Malignant neoplasm of lung
|
0.050 |
Biomarker
|
disease |
BEFREE |
Besides, miRNA-199 may inhibit the malignant progression of LCa by interacting with RGS17.
|
31081094 |
2019 |
|
Malignant neoplasm of lung
|
0.050 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNP) on chromosomal regions 5p15.33, 6p21.33, 6q23-25/RGS17, and 15q24-25.1 were assessed for their associations with familial lung cancer.
|
20142248 |
2010 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNP) on chromosomal regions 5p15.33, 6p21.33, 6q23-25/RGS17, and 15q24-25.1 were assessed for their associations with familial lung cancer.
|
20142248 |
2010 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Besides, miRNA-199 may inhibit the malignant progression of LCa by interacting with RGS17.
|
31081094 |
2019 |
|
Primary malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Besides, miRNA-199 may inhibit the malignant progression of LCa by interacting with RGS17.
|
31081094 |
2019 |
|
Primary malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNP) on chromosomal regions 5p15.33, 6p21.33, 6q23-25/RGS17, and 15q24-25.1 were assessed for their associations with familial lung cancer.
|
20142248 |
2010 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
To understand the role of miRNAs in Regulator of G Protein Signaling 17 (RGS17)-induced NSCLC, we showed that miR-203 was downregulated during tumorigenesis, and inhibited the proliferation and invasion of lung cancer cells.
|
28921827 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
RGS17 plays an important role in the regulation of cancer cell proliferation, migration and invasion.
|
29559347 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In searching for potential downstream targets of miR-203, a regulator of G-protein signaling 17 (RGS17) entered our sight due to its active role in a variety of malignant tumors.
|
31298318 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
RGS17 plays an important role in the regulation of cancer cell proliferation, migration and invasion.
|
29559347 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Subsequently colony formation assays and CCK8 cell viability assay was used to test the proliferation of NPC cells, flow cytometry was used to determine the percentage of apoptotic cells, MMP kit and flow cytometry was used to measure the mitochondrial membrane potential, and a xenograft tumour model was attached to investigate the effects of RGS17 on the growth of NPC cells in vivo.
|
30464507 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
G-Protein Signaling Protein-17 (RGS17) Is Upregulated and Promotes Tumor Growth and Migration in Human Colorectal Carcinoma.
|
28337960 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
RGS17 inhibits tumorigenesis and improves 5-fluorouracil sensitivity in nasopharyngeal carcinoma.
|
30464507 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have experimentally verified the presence of a previously unknown IRA1/RGS17 fusion in the breast cancer cell line MCF7.
|
15326299 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To understand the role of miRNAs in Regulator of G Protein Signaling 17 (RGS17)-induced NSCLC, we showed that miR-203 was downregulated during tumorigenesis, and inhibited the proliferation and invasion of lung cancer cells.
|
28921827 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We studied the role of the regulator of G-protein signaling (RGS) family of proteins RGS17 in colorectal carcinoma growth and metastasis.
|
28337960 |
2018 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have experimentally verified the presence of a previously unknown IRA1/RGS17 fusion in the breast cancer cell line MCF7.
|
15326299 |
2004 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
RGS17 plays an important role in the regulation of cancer cell proliferation, migration and invasion.
|
29559347 |
2018 |
|
Familial (FPAH)
|
0.010 |
Biomarker
|
disease |
BEFREE |
RGS17 is a major candidate for the familial lung cancer susceptibility locus on chromosome 6q23-25.
|
19351763 |
2009 |